BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 14654535)

  • 1. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
    Giannopoulos A; Constantinides C; Fokaeas E; Stravodimos C; Giannopoulou M; Kyroudi A; Gounaris A
    Clin Cancer Res; 2003 Nov; 9(15):5550-8. PubMed ID: 14654535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mitomycin C for the treatment of superficial tumors of the bladder (Tis-Ta-T1) with one or more risk factors. Argentinian Cooperative Group of Oncourology (GCAO)].
    Villaronga A; Bellver E; Perli G; Pautaso O; Bengochea D; Roldán RA; Podskubska O; Belén R; Delgado G; Laberti O; Lando R; Rey H; Bengio R; Minuzzi L; Goldman E; Milman A; Sanguinetti O; Wernert O
    Arch Esp Urol; 1996 Mar; 49(2):133-8. PubMed ID: 8702323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer--results of a controlled prospective study.
    Stavropoulos NE; Hastazeris K; Filiadis I; Mihailidis I; Ioachim E; Liamis Z; Kalomiris P
    Scand J Urol Nephrol; 2002; 36(3):218-22. PubMed ID: 12201939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
    Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
    Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
    Kuroda K; Ishii N; Fukasawa K; Shirai M; Tajima M; Matsushima M; Miura K; Takanami M; Matsuhashi M; Kuwabara T; Matsumoto H; Sugita M
    Hinyokika Kiyo; 1998 Aug; 44(8):547-52. PubMed ID: 9783189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
    Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
    Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical research on prevention of recurrence of superficial bladder cancer--comparative study on clinical efficacy of bleomycin intravesical instillation and bestatin].
    Kumamoto Y; Tsukamoto T; Tamiya T; Takatsuka K; Furuya S; Yokoyama E; Honma A; Aoyama T; Tanda H; Kato S
    Hinyokika Kiyo; 1985 Oct; 31(10):1861-83. PubMed ID: 2418659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
    Serretta V; Morgia G; Altieri V; Di Lallo A; Ruggiero G; Salzano L; Battaglia M; Falsaperla M; Zito A; Sblendorio D; Melloni D; Allegro R;
    BJU Int; 2010 Jul; 106(2):212-7. PubMed ID: 20070299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
    Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
    Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
    Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
    Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of prophylactic treatment with intravesical epirubicin in recurrence of superficial bladder tumor].
    Pérez Mestre M; Cuñat Albert E; Francisco Mingol V; Arrufat Boix JM; Gallego Gómez J
    Arch Esp Urol; 1999 May; 52(4):345-50. PubMed ID: 10380324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
    Colombo R; Da Pozzo LF; Salonia A; Rigatti P; Leib Z; Baniel J; Caldarera E; Pavone-Macaluso M
    J Clin Oncol; 2003 Dec; 21(23):4270-6. PubMed ID: 14581436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
    Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
    J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.